Myokardia Sees Unusually High Options Volume (NASDAQ:MYOK)
Myokardia Inc (NASDAQ:MYOK) was the target of unusually large options trading on Thursday. Traders bought 8,222 call options on the company. This represents an increase of 16,022% compared to the typical volume of 51 call options.
MYOK stock traded down $0.28 during midday trading on Friday, reaching $71.23. The company had a trading volume of 4,163 shares, compared to its average volume of 358,423. The stock has a 50 day moving average price of $71.51 and a 200 day moving average price of $61.11. Myokardia has a fifty-two week low of $40.17 and a fifty-two week high of $78.28. The firm has a market capitalization of $3.27 billion, a PE ratio of -13.65 and a beta of 2.09.
In related news, insider William Fairey sold 2,899 shares of Myokardia stock in a transaction dated Saturday, February 1st. The stock was sold at an average price of $68.04, for a total value of $197,247.96. Following the completion of the transaction, the insider now directly owns 8,125 shares in the company, valued at $552,825. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Anastasios Gianakakos sold 5,000 shares of Myokardia stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $75.39, for a total value of $376,950.00. Following the completion of the transaction, the chief executive officer now owns 91,777 shares of the company’s stock, valued at $6,919,068.03. The disclosure for this sale can be found here. Insiders sold 89,828 shares of company stock valued at $6,099,362 over the last quarter. Insiders own 4.30% of the company’s stock.
MYOK has been the subject of a number of research reports. Maxim Group reiterated an “average” rating on shares of Myokardia in a research note on Monday, October 28th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Myokardia in a research note on Friday, February 7th. Morgan Stanley lifted their price target on Myokardia from $70.00 to $75.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Guggenheim reiterated a “buy” rating and issued a $86.00 price target on shares of Myokardia in a research note on Monday, January 27th. Finally, BidaskClub downgraded Myokardia from a “buy” rating to a “hold” rating in a research note on Saturday, January 18th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $82.36.
Myokardia Company Profile
MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.
Further Reading: Trading Ex-Dividend
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.